<DOC>
	<DOCNO>NCT01836614</DOCNO>
	<brief_summary>The purpose study determine intravenous lidocaine infusion ( compare placebo ) intraoperatively decrease time return bowel function postoperatively , decrease postoperative pain , diminish postoperative opioid requirement , minimize inflammatory marker shorten time discharge colorectal surgery .</brief_summary>
	<brief_title>Intravenous Lidocaine Infusion Management Post-operative Pain Colorectal Patients</brief_title>
	<detailed_description>Lidocaine amide local anesthetic analgesic anti-inflammatory property . Lidocaine infusion useful pain medication underutilized treat surgical , chronic , cancer pain child . The investigator propose examine perioperative use lidocaine infusion child undergo colorectal surgery involve abdominal incision . The investigator plan measure follow outcome : length stay hospital follow abdominal surgery , postoperative pain score , cumulative morphine consumption , incidence opioid adverse-effects : respiratory depression , sedation , nausea , vomit , time passage flatus , time first bowel movement end-tidal Sevoflurane operating room throughout surgery . The following laboratory value measure : serial lidocaine level pharmacokinetics safety level , Pro- anti-inflammatory cytokine measurement : IL-6 , IL-8 , IL-10 , IL-1RA genetic variant .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>male female child 115 year age ASA physical status 13 schedule colorectal surgery abdominal incision schedule complex urology surgical case ASA physical status &gt; 3 postoperative intubation plan ahead surgery history chronic use opioid history hepatic , renal , cardiac failure history organ transplant BMI &gt; 30 history cardiac arrhythmia history long QT syndrome history allergic reaction lidocaine similar agent history seizure disorder patient without Peripherally Inserted Central Catheter central access contraindication inhalation induction family history know patient susceptibility malignant hyperthermia</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>